MX2018005439A - Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas. - Google Patents

Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas.

Info

Publication number
MX2018005439A
MX2018005439A MX2018005439A MX2018005439A MX2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A MX 2018005439 A MX2018005439 A MX 2018005439A
Authority
MX
Mexico
Prior art keywords
compounds
addiction
drug abuse
treatment
oxadiazaspiro
Prior art date
Application number
MX2018005439A
Other languages
English (en)
Inventor
Almansa Rosales Carmen
ALEGRET-MOLINA Carlos
Virgili-Bernado Marina
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2018005439A publication Critical patent/MX2018005439A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos con actividad farmacológica contra el receptor sigma (s), y más en particular a compuestos oxadiazaespíricos con dicha actividad farmacológica, a procesos de preparación de tales compuestos, a composiciones farmacéuticas que los comprenden y a su uso en terapia, en particular contra el abuso y la adicción a las drogas.
MX2018005439A 2015-11-16 2016-11-15 Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas. MX2018005439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382566 2015-11-16
PCT/EP2016/001907 WO2017084752A1 (en) 2015-11-16 2016-11-15 Oxadiazaspiro compounds for the treatment of drug abuse and addiction

Publications (1)

Publication Number Publication Date
MX2018005439A true MX2018005439A (es) 2018-11-09

Family

ID=54707728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005439A MX2018005439A (es) 2015-11-16 2016-11-15 Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas.

Country Status (29)

Country Link
US (2) US10927128B2 (es)
EP (1) EP3377500B1 (es)
JP (1) JP6884974B2 (es)
KR (1) KR20180080327A (es)
CN (1) CN108349999A (es)
AR (1) AR106697A1 (es)
AU (1) AU2016356488B2 (es)
CA (1) CA3002286A1 (es)
CO (1) CO2018004665A2 (es)
DK (1) DK3377500T3 (es)
ES (1) ES2932000T3 (es)
HR (1) HRP20221343T1 (es)
HU (1) HUE060275T2 (es)
IL (1) IL259035B (es)
LT (1) LT3377500T (es)
MA (1) MA43250B1 (es)
MX (1) MX2018005439A (es)
MY (1) MY193423A (es)
PH (1) PH12018500814A1 (es)
PL (1) PL3377500T3 (es)
PT (1) PT3377500T (es)
RS (1) RS63734B1 (es)
SG (1) SG11201803153RA (es)
SI (1) SI3377500T1 (es)
TN (1) TN2018000122A1 (es)
TW (1) TWI756196B (es)
UA (1) UA123775C2 (es)
WO (1) WO2017084752A1 (es)
ZA (1) ZA201802845B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060275T2 (hu) 2015-11-16 2023-02-28 Esteve Pharmaceuticals Sa Hatóanyaggal való visszaélés és addikció kezelésére alkalmas oxadiazaspiro-vegyületek
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
KR20240063904A (ko) 2021-09-20 2024-05-10 에스테베 파마슈티칼스 에스에이 운동뉴런 변성 치료 또는 신경보호에 사용하기 위한 옥사디아자스피로 화합물
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244961A (en) * 1978-10-26 1981-01-13 Syntex (U.S.A.) Inc. 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
WO2005075484A2 (en) * 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
EP1790639B1 (en) * 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclic compounds and their use as cxcr4-antagonists
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
CN101228127B (zh) 2005-05-30 2012-05-16 Msdk.K.公司 哌啶衍生物
CN101203567A (zh) * 2005-06-07 2008-06-18 西巴特殊化学品控股有限公司 抗刮擦聚烯烃
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
CN101331124B (zh) 2005-10-19 2013-08-14 格吕伦塔尔有限公司 新颖的辣椒素受体配体和它们用于生产药物的用途
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP1829869A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
EP1847542A1 (en) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
WO2008105497A1 (ja) 2007-03-01 2008-09-04 Mitsubishi Tanabe Pharma Corporation ベンゾイミダゾール化合物およびその医薬用途
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
WO2009032667A1 (en) 2007-08-29 2009-03-12 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
MX2010008577A (es) 2008-02-06 2010-11-25 Astrazeneca Ab Compuestos.
EP2108643A1 (en) * 2008-04-10 2009-10-14 Laboratorios Del. Dr. Esteve, S.A. 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
GB201016912D0 (en) * 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2686325B1 (en) 2011-03-14 2016-12-14 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
WO2013052716A1 (en) * 2011-10-07 2013-04-11 Glaxosmithkline Llc Fatty acid synthase inhibitors
JPWO2013115294A1 (ja) 2012-01-31 2015-05-11 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之烷基衍生物
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物
WO2016122994A1 (en) 2015-01-29 2016-08-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
HUE060275T2 (hu) 2015-11-16 2023-02-28 Esteve Pharmaceuticals Sa Hatóanyaggal való visszaélés és addikció kezelésére alkalmas oxadiazaspiro-vegyületek

Also Published As

Publication number Publication date
BR112018009279A8 (pt) 2019-02-26
UA123775C2 (uk) 2021-06-02
US20210115062A1 (en) 2021-04-22
US20180327422A1 (en) 2018-11-15
PH12018500814A1 (en) 2018-10-29
IL259035B (en) 2021-06-30
PT3377500T (pt) 2022-11-25
MA43250B1 (fr) 2022-12-30
RU2018120748A3 (es) 2020-02-07
RS63734B1 (sr) 2022-12-30
HUE060275T2 (hu) 2023-02-28
KR20180080327A (ko) 2018-07-11
US11649248B2 (en) 2023-05-16
SG11201803153RA (en) 2018-06-28
WO2017084752A1 (en) 2017-05-26
AR106697A1 (es) 2018-02-07
JP2018533598A (ja) 2018-11-15
TW201731854A (zh) 2017-09-16
BR112018009279A2 (pt) 2018-11-06
TWI756196B (zh) 2022-03-01
EP3377500A1 (en) 2018-09-26
RU2018120748A (ru) 2019-12-05
ZA201802845B (en) 2021-10-27
MA43250A (fr) 2021-04-14
PL3377500T3 (pl) 2023-01-23
CO2018004665A2 (es) 2018-07-19
JP6884974B2 (ja) 2021-06-09
IL259035A (en) 2018-06-28
CN108349999A (zh) 2018-07-31
TN2018000122A1 (en) 2019-10-04
AU2016356488B2 (en) 2020-10-22
ES2932000T3 (es) 2023-01-09
EP3377500B1 (en) 2022-10-19
SI3377500T1 (sl) 2023-02-28
MY193423A (en) 2022-10-12
US10927128B2 (en) 2021-02-23
DK3377500T3 (da) 2022-11-21
AU2016356488A1 (en) 2018-05-10
CA3002286A1 (en) 2017-05-26
HRP20221343T1 (hr) 2022-12-23
LT3377500T (lt) 2022-12-12

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MY187540A (en) Compounds active towards bromodomains
TW201613901A (en) New compounds
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
PH12015502698B1 (en) Dual selective pi3 delta and gamma kinase inhibitors
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
PH12016502307B1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MY199091A (en) Therapeutic compounds
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
IN2014MU00303A (es)
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
IN2013MU03118A (es)
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
MX2018004776A (es) Compuestos oxaazaespiricos con actividad contral el dolor.